British Biotech (BBIOY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : British Biotech (BBIOY)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (6)	6/3/1996 8:29:00 PM
From: olduser	of 41

To all Regarding the Barron's story about Brit. Biotech, Please notice that the parameter used to measure the effectiveness of marimastat is the level of certain proteins. There is no mention of tumor mass reduction (or I guess lack of growth would be more appropriate) or survival rate statistics. On the basis of this article, valid conclusions regarding the effectiveness of the drug can not be drawn. On the upside is the comment about side effects: joint swelling and/or pain will certainly not preclude use in end stage cancer patients. Also, in general an enzyme inhibitor can loose effectiveness in a model where cell turnover and the ablity for mutations are high. I hope to God the drug is good, but more data is needed to form opinions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next